Impact of reflectance confocal microscopy on the physician’s diagnostic confidence and decision making of equivocal skin tumors: Outcomes after one-year follow-up - 03/08/18
Oriol Yelamos, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York; Elena Manubens, MD, Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona; Stephen Dusza, MPH, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Michael A. Marchetti, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Alicia Barreiro, MD, Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Spain; Josep Malvehy, MD, Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona; Anthony M. Rossi, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Susana Puig, MD, Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Spain; Ashfaq A. Marghoob, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Cristina Carrera, MD, Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Spain
Le texte complet de cet article est disponible en PDF. Commercial support: Milind Rajadhyaksha is a former employee of and owns equity in Caliber Imaging and Diagnostics (formerly Lucid, Inc.), the company that manufactures and sells the Vivascope confocal microscope. |
Vol 79 - N° 3S1
P. AB160 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?